Merck, the global science and technology company, announced a major expansion of its manufacturing site in Peenya, Bangalore.
The investment will add new production lines for the filtration hardware system of 2025, followed by Pellicon 2 Ultrafiltration Cassette 2026.
“These products are essential to producing life-saving medicines and vaccines,” said Tony Qiu, Head of APAC Operations, Life Science Business at Merck. “By expanding manufacturing in India, the company is strengthening global supply chains while supporting local innovation and skills.”
India’s Growing Biotech Hub
Bangalore has long been recognized as India’s “Silicon Valley,” but in recent years it has also emerged as a biotech powerhouse. The city hosts a cluster of pharmaceutical and life sciences companies, research institutes, and startups, making it a natural choice for Merck’s expansion.
Peenya Facility’s Role
Merck’s Peenya site has been a hub for filtration hardware since 2006 and began producing consumables such as prefilter cartridges in 2022. The latest expansion reinforces India’s position in Merck’s global network, ensuring faster access to advanced purification technologies. The Pellicon 2 Ultrafiltration Cassette supports a wide range of applications in pharma and life sciences.
Local Impact and Global Reach
The expansion is expected to generate skilled jobs, strengthen vendor ecosystems, and boost India’s reputation as a reliable manufacturing base. For Merck, it represents an investment in Asia-Pacific, ensuring that critical filtration technologies are available to global customers.
Industry experts note that such moves highlight India’s transition from being primarily a generics producer to becoming a hub for advanced biotech manufacturing.
